Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 243

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 243
---
e       |     |  63 |     | Director                             |
| Lindsey Rolfe, M.D.    |     |  56 |     | Director                             |
| Shami Patel            |     |  55 |     | Director                             |

Executive Officers

Chris Ehrlich has
served as our Chairman and Chief Executive Officer since December 2024. From October 2024 to November 2024, he served as the interim
Chairman and Chief Executive Officer. Prior to this, he served as the Vice Chairman of our board of directors from February 2024 to October
2024. He previously served as the Chief Executive Officer of PBAX from October 2021 until the Closing of the Business Combination in
February 2024. From January 2021 to August 2021, he served as the Chief Executive Officer of Locust Walk Acquisition Corp (Nasdaq: LWAC)
until it merged with eFFECTOR Therapeutics, Inc. He is also the Principal of Ehrlich Bioventures, LLC, a consultancy working with emerging
biopharma companies. He previously served as Senior Managing Director and the Global Head of Strategic Transactions at Locust Walk Partners
from 2013 to 2021. He brings significant biotechnology industry, business development, venture capital experience, investment banking
and SPAC experience. While at Locust Walk Partners, Mr. Ehrlich was involved with sourcing and leading multiple transactions for
emerging biopharmaceutical companies, including the sale of Xyphos Biosciences, Inc. to Astellas in 2019 and the sale of Thar Pharmaceuticals
to Grunenthal in 2018. Prior to Locust Walk Partners, he was a Managing Director at InterWest Partners (“InterWest”),
a venture capital firm. At InterWest, he served on the boards of KAI Pharmaceuticals, a privately held pharmaceutical company (acquired
by Amgen in 2012), Biomimetic Therapeutics, Inc., a biotechnology company (acquired by Wright Medical Technologies in 2013), Invuity,
Inc., a medical technology company acquired by Stryker in 2018) and Xenon Pharmaceuticals, a biopharmaceutical company (Nasdaq: XENE).
Prior to joining InterWest, Mr. Ehrlich worked as the Director of Licensing and Business Development at Purdue Pharma, in business
development at Genentech, in venture capital at the U.S. Russia Investment Fund, and in bi